Abilify
In brief
- In our pharmacy, you can buy Abilify without a prescription, with delivery in 9–21 days throughout the United Kingdom. Discreet and anonymous packaging.
- Abilify (aripiprazole) is used to treat schizophrenia, bipolar I disorder (mania/mixed), and prevention of manic episodes; it is an atypical antipsychotic that acts as a partial agonist at dopamine D2 and serotonin 5‑HT1A receptors and as an antagonist at 5‑HT2A receptors, modulating dopaminergic and serotonergic signalling.
- Usual doses: adults with schizophrenia typically 15 mg daily (range 10–30 mg/day); bipolar mania about 15 mg daily; adolescent dosing is lower and titrated; long‑acting injectables: Maintena 300 mg or 400 mg monthly, Asimtufii 720 mg every 2 months.
- Forms of administration: oral tablets (5, 10, 15, 30 mg), orally disintegrating tablets (ODT, 10 and 15 mg), oral solution (1 mg/mL) and intramuscular long‑acting injections (monthly or bimonthly depot preparations).
- Onset time: some symptoms (eg agitation, sleep, anxiety) may improve within a few days, but meaningful antipsychotic or antidepressant response usually requires 2–6 weeks of treatment.
- Duration of action: oral dosing is taken once daily with effects maintained while treatment continues (24‑hour coverage per dose); long‑acting injectables provide therapeutic levels for one month (Maintena) or two months (Asimtufii) depending on the product.
- Alcohol warning: avoid alcohol while taking Abilify as alcohol can increase sedation, impair coordination and cognition, and may worsen side effects such as dizziness and low blood pressure.
- The most common side effect is akathisia (restlessness); other frequent adverse effects include insomnia, headache, nausea, constipation, dizziness, tremor and mild weight gain.
- Would you like to try Abilify without a prescription?
Basic Abilify information
- INN (international nonproprietary name): Aripiprazole
- Brand names available in the United Kingdom: Abilify, Abilify Maintena, Abilify Asimtufii; generic aripiprazole
- ATC code: N05AX12
- Forms and dosages: tablets 5 mg, 10 mg, 15 mg, 30 mg; orodispersible tablets 10 mg, 15 mg; oral solution 1 mg/mL; long-acting injections (Maintena 300 mg/400 mg monthly; Asimtufii 720 mg every two months)
- Manufacturers in the United Kingdom: Otsuka (originator) and generic manufacturers
- Registration status in the United Kingdom: authorised by the MHRA; prescription-only medicine (POM)
- OTC / Rx classification: Prescription-only medicine (POM)
Legal status and availability in the UK
Abilify (aripiprazole) is a prescription-only medicine (POM) in the UK.
In our online pharmacy, Abilify is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.
Forms and strengths
The active ingredient is aripiprazole (INN). Abilify is the originator brand (Otsuka); depot products are Abilify Maintena (monthly) and Abilify Asimtufii (every two months).
| Form | Strengths |
|---|---|
| Tablets | 5 mg, 10 mg, 15 mg, 30 mg |
| Orodispersible tablets | 10 mg, 15 mg |
| Oral solution | 1 mg/mL |
| Long-acting injection | Maintena 300 mg/400 mg; Asimtufii 720 mg (every two months) |
Generic aripiprazole is available from several manufacturers.
Indications and prescribing uses
Licensed uses and NHS practice
- Schizophrenia — adults: usual starting and target dose 15 mg/day, range 10–30 mg/day; adolescents from 15 years are started on a low dose and titrated slowly in line with the product information.
- Bipolar I disorder (manic or mixed episodes) — adults: commonly 15 mg/day; adolescents from 13 years are started on a low dose and titrated slowly; also used to prevent new manic episodes.
On the NHS depot injections are usually initiated by a specialist team, with primary care commonly following up oral maintenance therapy under shared‑care protocols.
Off‑label uses seen in practice include augmentation in treatment‑resistant depression (usually 2–5 mg/day, judged over at least 6–8 weeks) and management of irritability in autism spectrum disorder or tics under specialist care.
Dosage, titration and administration
Typical adult and adolescent regimens
| Indication | Usual start | Typical maintenance | Maximum |
|---|---|---|---|
| Schizophrenia (adult) | 15 mg/day | 10–30 mg/day as needed | 30 mg/day |
| Bipolar mania | 15 mg/day | 15 mg/day | 30 mg/day |
| Adolescents (schizophrenia from 15 years, mania from 13 years) | Start low and titrate slowly | Follow the product information | Lower maximum than adults per SPC |
Orally disintegrating tablets should be placed on the tongue and allowed to disperse; do not crush standard film‑coated tablets unless advised.
Oral solution is 1 mg/mL; use an oral syringe for accurate dosing and rinse the syringe after use.
Long‑acting injectable initiation follows loading or overlap schedules as per the product summary and is arranged by the specialist team.
Aripiprazole can be taken with or without food.
To reduce insomnia consider taking doses earlier in the day unless sedation is a problem, in which case dosing at night may help.
If a dose is missed take it the same day if remembered but do not double the next dose.
Clinical efficacy, onset and monitoring timeline
What to expect
Partial improvements such as better motivation and sleep are often seen within 1–2 weeks of starting aripiprazole.
Full antipsychotic effects typically take several weeks and clinicians usually assess response over that period.
For adjunctive treatment in major depressive disorder allow 6–8 weeks to judge clinical response before changing strategy.
Baseline monitoring recommended includes weight, blood pressure, fasting glucose and lipid profile in line with MHRA and NICE guidance.
Repeat checks are typically done at 3 months and then annually, or sooner if clinical signs indicate metabolic change.
Any dose changes should align with NHS or specialist pathways and a specialist review is recommended for significant adjustments.
| Time point | Action |
|---|---|
| Baseline | Weight, BP, fasting glucose, lipids |
| 4–8 weeks | Assess clinical response and side effects |
| 3 months | Repeat metabolic checks |
| 6–12 months | Annual review and ongoing monitoring |
Side effects and practical management
Common and serious effects, and when to seek help
Common adverse effects include akathisia, insomnia, headache, nausea, constipation, dizziness, mild sedation, transient weight gain and tremor.
Serious effects to report include extrapyramidal symptoms, worsening suicidality, neuroleptic malignant syndrome, severe hyperglycaemia and orthostatic hypotension.
| Symptom | First step | Seek urgent help if |
|---|---|---|
| Akathisia (restlessness) | Discuss timing and dose with the prescriber; any treatment for akathisia is a clinician decision | Severe distress or inability to sit/stand |
| Constipation | Laxative and lifestyle advice | Severe abdominal pain or vomiting |
| Sedation/dizziness | Advise on timing of dosing, avoid driving until stable | Fainting, prolonged dizziness |
| Weight/metabolic change | Lifestyle support and regular metabolic monitoring | Marked hyperglycaemia or signs of diabetic decompensation |
Seek urgent medical help for fever, severe muscle rigidity, breathing difficulty or inability to swallow. Tell the prescriber promptly about persistent or severe side effects.
Drug interactions and biochemical cautions
CYP interactions, additive effects and monitoring
Aripiprazole is metabolised primarily via CYP2D6 and CYP3A4 pathways.
Coadministration with potent CYP3A4 inhibitors such as some azole antifungals or clarithromycin may increase aripiprazole levels and require specialist advice.
CYP3A4 inducers such as carbamazepine can reduce aripiprazole exposure and dose adjustments may be needed under clinician supervision.
| Interactor | Effect | What to do |
|---|---|---|
| CYP3A4 inhibitors (e.g. some azoles, clarithromycin) | May ↑ aripiprazole levels | Tell the prescriber; specialist review advised |
| CYP3A4 inducers (e.g. carbamazepine) | May ↓ aripiprazole levels | Prescriber may change the dose |
| Other dopamine antagonists | Additive extrapyramidal risk | Monitor for movement side effects; tell the prescriber |
| QT‑prolonging drugs | Potential cumulative QT risk | Cardiac history should be checked; seek advice if there is arrhythmia risk |
Biochemical cautions include monitoring glucose, lipids and liver function tests where clinically indicated.
Contraindications and cautions by population
Elderly, pregnancy, hepatic/renal impairment
Absolute contraindication: known hypersensitivity to aripiprazole or any product ingredients.
Elderly patients with dementia‑related psychosis have an increased mortality risk and aripiprazole should be used with caution at the lowest effective dose and with close monitoring.
Pregnancy and lactation: weigh maternal benefit against potential foetal or neonatal risks and seek specialised obstetric and psychiatric advice.
Severe hepatic impairment is a caution; although routine dose adjustments are not universally required, monitor closely if severe disease is present.
Renal impairment generally does not require standard dose adjustment but use cautiously and review clinical response.
History of seizures, cardiovascular disease or diabetes should prompt extra monitoring and liaison with the prescriber.
Long‑acting injectables
Maintena and Asimtufii
| LAI product | Dose interval | Initiation notes | Storage |
|---|---|---|---|
| Abilify Maintena | Monthly (300 mg or 400 mg) | Clinic administration; loading/overlap per SPC | Protect from freezing |
| Abilify Asimtufii | Every two months (720 mg) | Clinic administration; specialist initiation required | Protect from freezing |
LAIs are administered intramuscularly (gluteal or deltoid) by trained staff in clinic settings. Regular clinic contact can support adherence and reduce relapse risk when used appropriately.
Storage, handling, missed doses and overdose advice
Home storage and emergency steps
Tablets and ODTs should be stored at room temperature, typically 15–30°C, in the original container and kept dry.
Oral solution should be protected from light and discarded if discoloured.
Missed‑dose advice: take as soon as remembered if still the same day, skip if close to the next dose and do not double up.
An overdose can be harmful, so seek medical help promptly (NHS 111, or 999 in an emergency); possible symptoms include drowsiness, vomiting, agitation, tachycardia and seizures.
Delivery across the United Kingdom
| City | Region | Delivery Time |
|---|---|---|
| London | England | 9–21 days |
| Birmingham | England | 9–21 days |
| Manchester | England | 9–21 days |
| Glasgow | Scotland | 9–21 days |
| Edinburgh | Scotland | 9–21 days |
| Bristol | England | 9–21 days |
| Leeds | England | 9–21 days |
| Cardiff | Wales | 9–21 days |
| Belfast | Northern Ireland | 9–21 days |
| Newcastle | England | 9–21 days |
| Nottingham | England | 9–21 days |
| Southampton | England | 9–21 days |
| Plymouth | England | 9–21 days |
| Aberdeen | Scotland | 9–21 days |
